NCT07068490 Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.
| NCT ID | NCT07068490 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 100,000 participants |
| Start Date | 2024-10-22 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100,000 participants in total. It began in 2024-10-22 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.
Eligibility Criteria
Inclusion Criteria: * Patients who underwent PCI * Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin * No use of PCAB, PPI, or an H2-receptor within the past month Exclusion Criteria: * Patients with low GI bleeding risk are taken on PPI * Patients with high GI bleeding risk do not take PPI
Contact & Investigator
KI HONG CHOI, MD, PhD
PRINCIPAL INVESTIGATOR
Samsung Medical Center
Frequently Asked Questions
Who can join the NCT07068490 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07068490 currently recruiting?
Yes, NCT07068490 is actively recruiting participants. Contact the research team at cardiokh@gmail.com for enrollment information.
Where is the NCT07068490 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07068490 clinical trial?
NCT07068490 is sponsored by Samsung Medical Center. The principal investigator is KI HONG CHOI, MD, PhD at Samsung Medical Center. The trial plans to enroll 100,000 participants.